Resources Repository
-
ReportPublication 2021Valuing COVID-19 Mortality and Morbidity Risks
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk …
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk reductions that builds on the U.S. Department of Health and Human Services (HHS) Guidelines for Regulatory Impact Analysis. They review the differences between COVID-19 mortality risks and the types of risks that are more commonly studied, and find that the impacts of these differences on the value of mortality risk reductions (the value per statistical life, VSL) are uncertain. They…
Government/Law | North America | Preferences/Values | Benefit-Cost Analysis | Infectious Diseases | Policy/Regulation -
ReportPublication 2017Underestimated Cost of the Opioid Crisis
This report on the opioid public health crisis was released by the White House Council …
This report on the opioid public health crisis was released by the White House Council on Economic Advisors (CEA) in November 2017. It corrects previous estimates of related costs by adding the value of the associated deaths. Earlier estimates focused on medical and other expenditures, while the new report also includes estimates of the value that individuals place on reducing their own risks of premature mortality. The report notes that, in 2015, over 33,000 Americans…
Government/Law | North America | Preferences/Values | Costing Methods | Benefit-Cost Analysis | Chronic Disease/Risk | Mental Health | Policy/Regulation | Economics/Finance | Health/Medicine -
ReportPublication 2018Estimating the Distributional Impact of Increasing Taxes on Tobacco Products in Armenia
Smoking is considered the leading risk factor for mortality among the Armenian population. The authors …
Smoking is considered the leading risk factor for mortality among the Armenian population. The authors conducted an extended cost-effectiveness analysis (ECEA) on increases in the excise tax on cigarettes in Armenia. Based on the World Health Organization recommendations, they analyzed the impact of a 75% increase of excise tax on the retail price of cigarettes. The ECEA found large health and financial benefits to the excise tax. It averted about 88,000 premature deaths, US$63 million of OOP…
Government/Law | Europe | Priority Setting/Ethics | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Policy/Regulation | Business/Industry | Economics/Finance | Health/Medicine -
ReportPublication 2016Modeling to Inform Strategies to Improve Population Health
This workshop report summarizes a workshop convened by the Institute of Medicine to explore the potential …
This workshop report summarizes a workshop convened by the Institute of Medicine to explore the potential uses of simulation and other types of modeling for improving health. Participants worked to identify how modeling could inform population health decision making (selecting and refining potential strategies, ranging from interventions to investments) based on lessons learned from models that have been, or have not been, used successfully, opportunities and barriers to incorporating models into decision making, and data needs and…
Government/Law | North America | Mathematical Models | State-Transition | Microsimulation | Dynamic Simulation | Decision Analysis | Chronic Disease/Risk | Environmental Health | Health Systems | Policy/Regulation | Business/Industry | Climate/Environment | Health/Medicine -
ReviewWeb Portal 2016Use of Economics in Informing U.S. Public Health Policy
The goal of this American Journal of Preventive Medicine supplement on “The Use of Economics …
The goal of this American Journal of Preventive Medicine supplement on “The Use of Economics in Informing U.S. Public Health Policy” is to influence policy researchers to identify and undertake economic research that generates the key evidence needed to inform policy. In public health, economic evaluation, primarily cost and cost-effectiveness analysis, has been widely used to demonstrate the economic burden of health-related conditions and the value of proposed programs and policies. However, despite the wealth…
Government/Law | North America | Priority Setting/Ethics | Costing Methods | Health Outcomes | Cost-Effectiveness Analysis | Health Systems | Policy/Regulation | Economics/Finance | Health/Medicine -
ReviewPublication 2015Medicare's Use of CEA for Prevention (But Not Treatment)
Medicare currently pays for 23 preventive services in its benefits package, the majority of which …
Medicare currently pays for 23 preventive services in its benefits package, the majority of which were added since 2005. In the past decade, the program has transformed from one essentially administering treatment claims, to one increasingly focused on health promotion and maintenance. What is largely unappreciated is the role cost-effectiveness analysis has played in the coverage of preventive services. This study reviews the role of cost-effectiveness analysis in Medicare coverage of preventive services and contrast it…
Government/Law | North America | Priority Setting/Ethics | Cost-Effectiveness Analysis | Technology Assessment | Infectious Diseases | Child/Nutrition | Chronic Disease/Risk | Health Systems | Policy/Regulation | Economics/Finance | Health/Medicine -
ReportPublication 2015Opioid Dependence: Final Report
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value …
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value of interventions for the management of opioid dependence. The goals of the report are to document the federal and New England state regulations affecting treatment options, provide an overview of existing clinical guidelines and payer coverage policies, and summarize the evidence on the different management approaches for opioid dependence, including special considerations for adolescents. An appendix is provided by ICER.…
Government/Law | North America | Preferences/Values | Health Outcomes | Evidence Synthesis | Cost-Effectiveness Analysis | Technology Assessment | Chronic Disease/Risk | Mental Health | Health Systems | Policy/Regulation | Business/Industry | Health/Medicine | Science/Technology -
ReportPublication 2014Redirecting Innovation in U.S. Health Care
This report from RAND Health explores methods of reducing health care spending and developing medical …
This report from RAND Health explores methods of reducing health care spending and developing medical products that provide cost value with health benefits. It summarizes literature and explores case studies to provide policy recommendations to meet these goals. It identifies a wide range of factors that affect the costs, risks, and rewards of medical product invention. Some of these features include treatment creep, the medical arms race, costs and risks of FDA approval, limited reward…
Government/Law | North America | Costing Methods | Health Outcomes | Evidence Synthesis | Health Systems | Policy/Regulation | Economics/Finance | Health/Medicine | Science/Technology -
ReviewPublication 2013Valuing the Economic Benefits of Complex Interventions
This is a review of economic evaluations of complex health interventions. Complex interventions, involving interlinked …
This is a review of economic evaluations of complex health interventions. Complex interventions, involving interlinked packages of care, challenge the application of current methods of economic evaluation that focus on measuring only health gain. The authors find that complex interventions may be problematic on two levels. First, the complexity means the intervention may not fit into one of the current appraisal systems, and/or second, maximizing health is not the only objective. This paper discusses the…
Government/Law | Europe | Preferences/Values | Decision Analysis | Health Systems | Policy/Regulation | Economics/Finance | Health/Medicine | Science/Technology